Simple Clinical Predictors of Successful Fibrinolysis in Combined Assessment of ST-Segment Resolution, Myocardial Infraction Flow Grade, and Myocardial Perfusion Grade: Importance of Admission Blood Glucose and Ischemic Time

Fahmy Rusnanta, Mohammad Saifur Rohman, Indra Prasetya, Ardian Rizal, Novi Kurnianingsih


Background Fibrinolytic therapy (FT) is the alternative recommendation in patients with ST-segment elevation myocardial infarction (STEMI) if primary percutaneous coronary intervention (PCI) could not be perfomed timely at initial presentation. Successful revascularization of occluded infarct-related coronary arteries depends on complex mechanisms of hemodynamic, clinical, biochemical, and mechanical parameters. The aim of study was to find outpredictors of patient characteristics to achieve complete reperfusion based on Thrombolysis in Myocardial Infarction(TIMI) 3 flow, Myocardial Blush Grade (MBG) 3, and ST-segment resolution.  


Method : This retrospective study was held in Saiful Anwar, Malang Hospital during 2017-2021, including total of 142 patients. All patients received FT and coronary angiographic evaluation post-FT. Those were divided into 3 groups, which included R0,1 (0/1 highest measure of reperfusion), R2 (2 highest measures of reperfusion), and R3 (3 highest measures of reperfusion).


Results : Ischemic time (OR 0,82 [95%CI -0,39;-0,01]; p=0,04] and admission blood glucose (ABG) (OR 0,99 [95%CI -0,01;0]; p=0,046] were negatively correlated to the complete restoration of reperfusion (R3). This study revealed that ischemic time <5 hours (AUC 0,742 [95%CI 0,645-0,839]; p=0,000)  and ABG <140 mg/dL (AUC 0,701 [95%CI 0,612-0,790]; p=0,000) were significant predictor for R≥2. Coronary characteristic was not related to measure of reperfusion (p=0,25).


Conclusion : Ischemic time <5 hours and ABG <140 mg/dL are important predictors of successful reperfusion post FT (R≥2). Early assessment of patients who are likely to have low parameter reperfusion (R<2) would help promptly preparing for primary PCI.


STEMI, fibrinolytic therapy, coronary angiography, ischemic time, blood glucose

Full Text:



Kocas C, Abaci O, Halil GS, Arslan S, Cetinkal G, Bostan C, dkk. Admission hyperglycemia is associated with failed reperfusion following fibrinolytic therapy in patients with STEMI: results of a retrospective study. Am J Cardiovasc Drugs. 2015;15(1):35-42.

Lundergan CF, Reiner JS, McCarthy WF, Coyne KS, Califf RM, Ross AM. Clinical predictors of early infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: the GUSTO-I experience. JACC. 1998;32(3):641-7.

Brener SJ, Dizon JM, Mehran R, Guerchicoff A, Lansky AJ, Farkouh M, dkk. Complementary prognostic utility of myocardial blush grade and ST-segment resolution after primary percutaneous coronary intervention: analysis from the HORIZONS-AMI trial. Am Heart J;166(4):676-83.

Giugliano RP, Sabatine MS, Gibson CM, Roe MT, Harrington RA, Murphy SA, dkk. Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. Am J Cardiol. 2004;93(11):1362-7.

Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569–619.

American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):e78–140.

Dharma S, Andriantoro H, Dakota I, Purnawan I, Pratama V, Isnanijah H, dkk. Organisation of reperfusion therapy for STEMI in a developing country. Open Heart. 2015;2(1):1-8.

Wahab NN, Cowden EA, Pearce NJ, Gardner MJ, Merry H, Cox JL. Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era? J Am Coll Cardiol. 2002;40:1748–54.

Rosencher J, Bongard V, Tazarourte K, OPTIMAL investigators. A simple nomogram for early prediction of myocardial reperfusion after pre-hospital thrombolysis. EuroIntervention. 2011;7(2):248–55.

Shah A, Wagner GS, Granger CB, O’Connor CM, Green CL, Trollinger KM, et al. Prognostic implications of TIMI flow grade in the infarct related artery compared with continuous 12-lead ST-segment resolution analysis. Reexamining the ‘‘gold standard’’ for myocardial reperfusion assessment. J Am Coll Cardiol. 2000;35:666–72.

van ’t Hof AW, Liem A, de Boer MJ, Zijlstra F. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial infarction Study Group. Lancet. 1997;350:615–9.

Costantini CO, Stone GW, Mehran R, et al. Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. J Am Coll Cardiol 2004; 44(2):305-12.

Silvain J, Collet JP, Nagaswami C, Beygui F, Edmondson KE, Bellemain-Appaix A, dkk. Composition of coronary thrombus in acute myocardial infarction. JACC. 2011;57(12):1359-67.

Boersma E. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J. 2006;27:779 – 88.

Ariens RA, Lai TS, Weisel JW, Greenberg CS, Grant PJ. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood. 2002;100:743–54.

Cheung NW, Wong VW, McLean M. The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care. 2006;29:765–70.

Malmberg K, Ryde´n L, Wedel H, Birkeland K, Bootsma A, Dickstein K, et al, DIGAMI 2 Investigators. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005;26:650–61.

Jörneskog G, Egberg N, Fagrell B, Fatah K, Hessel B, Johnsson H, et al. Altered properties of the fibrin gel structure in patients with IDDM. Diabetologia. 1996;39:1519-23.

Alzahrani SH, Ajjan RA. Coagulation and fibrinolysis in diabetes. Diabetes and Vascular Disease Research. 2010;7(4):260-73.

Iwakura K, Ito H, Ikushima M, Kawano S, Okamura A, Asano K, dkk. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol. 2003;41(1):1-7.

Yildiz A, Arat-Ozkan A, Kocas C, Abaci O, Coskun U, Bostan C, et al. Admission hyperglycemia and TIMI frame count in primary percutaneous coronary intervention. Angiology. 2012;63(5):325–9.

Rao KR, Reddy S, Kashyap JR, Ramalingam V, Dash D, Kadiyala V, dkk. Association of culprit lesion plaque characteristics with flow restoration fibrinolysis in ST-segment elevation myocardial infarction: an intravascular ultrasound-virtual histology study. Egypt Heart J. 2020;72(1):86.



  • There are currently no refbacks.

Copyright (c) 2021 Fahmy Rusnanta, Mohammad Saifur Rohman, Indra Prasetya, Ardian Rizal, Novi Kurnianingsih

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.